调节PD-1/PD-L1信号通路在治疗自身免疫病中的研究进展  

Research progress in regulating PD-1/PD-L1 signaling pathway in the treatment of autoimmune diseases

作　　者：冯俊娟(综述) 石艳春[1] 陈国江(审校) FENG Junjuan;SHI Yanchun;CHEN Guojiang(Inner Mongolia Key Laboratory of Molecular Biology,Inner Mongolia Medical University,Hohhot 010058,Inner Mongolia,China;不详)

机构地区：[1]内蒙古医科大学分子生物学重点实验室,内蒙古呼和浩特010058 [2]军事科学院军事医学研究院抗毒药物与毒理学国家重点实验室,北京100850

出　　处：《微生物学免疫学进展》2023年第5期68-73,共6页Progress In Microbiology and Immunology

基　　金：国家自然科学基金(81672803,81871252)。

摘　　要：程序性死亡蛋白1(programmed death 1,PD-1)与程序性死亡蛋白配体1(programmed death ligand 1,PD-L1)结合能启动负调控信号,并抑制机体的过度反应,从而维持人体的免疫耐受和免疫稳态。PD-1/PD-L1信号被认为是机体的一种自我保护机制,若其功能受损将会导致多种自身免疫病的发生,如Ⅰ型糖尿病(diabetes mellitus typeⅠ)、多发性硬化症(multiple sclerosis)等。因此,调节PD-1/PD-L1信号已成为治疗自身免疫病的一种新策略。现就PD-1/PD-L1途径在自身免疫病中的作用及调节PD-1/PD-L1信号治疗自身免疫病的最新研究进展作一概述。The binding of programmed death 1(PD-1) to programmed death ligand 1(PD-L1) initiates negative regulatory signals and inhibits the overreaction of the body,which maintains immune tolerance and immune homeostasis.PD-1/PD-L1 signaling is regarded as a self-protection mechanism of the body,and its impaired function will lead to the development of many autoimmune diseases,such as diabetes mellitus type I and multiple sclerosis,etc.Therefore,regulation of PD-1/PD-L1 signaling has become a new therapeutic option for autoimmune diseases.This article reviews the role of PD-1/PD-L1 pathway in autoimmune diseases and the latest research progress in regulating PD-1 signaling for autoimmune diseases.

关 键 词：程序性死亡蛋白1 程序性死亡蛋白配体1 信号 激动剂 自身免疫病 双特异性分子 小分子抑制剂 功能模拟 

分 类 号：R392.9[医药卫生—免疫学]